False-positive HIV diagnoses: lessons from Ugandan and Russian research cohorts.

Q2 Medicine HIV Clinical Trials Pub Date : 2018-02-01 Epub Date: 2018-01-31 DOI:10.1080/15284336.2018.1429846
Sharon M Coleman, Natalia Gnatienko, Christine A Lloyd-Travaglini, Michael R Winter, Carly Bridden, Elena Blokhina, Dmitry Lioznov, Julian Adong, Jeffrey H Samet, Teri Liegler, Judith A Hahn
{"title":"False-positive HIV diagnoses: lessons from Ugandan and Russian research cohorts.","authors":"Sharon M Coleman, Natalia Gnatienko, Christine A Lloyd-Travaglini, Michael R Winter, Carly Bridden, Elena Blokhina, Dmitry Lioznov, Julian Adong, Jeffrey H Samet, Teri Liegler, Judith A Hahn","doi":"10.1080/15284336.2018.1429846","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Research studies rely on accurate assessment of entry criteria in order to maintain study integrity and participant safety, however, challenges can exist with HIV studies in international settings.</p><p><strong>Objective: </strong>Examine the unexpectedly high proportion of study participants with an undetectable HIV viral load found in Ugandan and Russian research cohorts meeting antiretroviral therapy (ART)-naïve entry criteria.</p><p><strong>Methods: </strong>Russian participants with documented HIV and ART-naïve status were recruited between 2012 and 2015 from clinical and non-clinical sites in St. Petersburg. Participants in Uganda were recruited from Mbarara Regional Referral Hospital from 2011 to 2014 with documented HIV infection via rapid diagnostic testing and recorded ART-naïve in the clinic database. HIV viral load testing of baseline samples was performed; the lower limit of detection was 500 copies/mL in Russia and 40 in Uganda. Due to an unexpectedly high proportion of participants with undetectable viremia, additional tests were performed: enzyme-linked immunosorbent assay HIV testing and testing for ART.</p><p><strong>Results: </strong>In Russia, 16% (58/360) had undetectable viremia; 3% (9/360) re-tested HIV-seronegative and 4% (13/360) tested positive for ART. In Uganda 11% (55/482) had undetectable viremia; 5% (26/482) re-tested HIV-seronegative, while <1% (4/482) tested positive for ART.</p><p><strong>Conclusions: </strong>In both Russia & Uganda, undetectable viremia was much higher than would be expected for an HIV-infected ART-naïve cohort. Misclassification of study participants was due to misdiagnosis of HIV with rapid diagnostic testing and inaccurate accounting of ART use. Confirmatory HIV testing could improve accuracy of participants meeting entry criteria for HIV infection as might increased scrutiny of medication use in an ART-naïve cohort.</p>","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949866/pdf/nihms958843.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15284336.2018.1429846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Research studies rely on accurate assessment of entry criteria in order to maintain study integrity and participant safety, however, challenges can exist with HIV studies in international settings.

Objective: Examine the unexpectedly high proportion of study participants with an undetectable HIV viral load found in Ugandan and Russian research cohorts meeting antiretroviral therapy (ART)-naïve entry criteria.

Methods: Russian participants with documented HIV and ART-naïve status were recruited between 2012 and 2015 from clinical and non-clinical sites in St. Petersburg. Participants in Uganda were recruited from Mbarara Regional Referral Hospital from 2011 to 2014 with documented HIV infection via rapid diagnostic testing and recorded ART-naïve in the clinic database. HIV viral load testing of baseline samples was performed; the lower limit of detection was 500 copies/mL in Russia and 40 in Uganda. Due to an unexpectedly high proportion of participants with undetectable viremia, additional tests were performed: enzyme-linked immunosorbent assay HIV testing and testing for ART.

Results: In Russia, 16% (58/360) had undetectable viremia; 3% (9/360) re-tested HIV-seronegative and 4% (13/360) tested positive for ART. In Uganda 11% (55/482) had undetectable viremia; 5% (26/482) re-tested HIV-seronegative, while <1% (4/482) tested positive for ART.

Conclusions: In both Russia & Uganda, undetectable viremia was much higher than would be expected for an HIV-infected ART-naïve cohort. Misclassification of study participants was due to misdiagnosis of HIV with rapid diagnostic testing and inaccurate accounting of ART use. Confirmatory HIV testing could improve accuracy of participants meeting entry criteria for HIV infection as might increased scrutiny of medication use in an ART-naïve cohort.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
艾滋病毒诊断假阳性:乌干达和俄罗斯研究队列的经验教训。
背景:研究依赖于对入选标准的准确评估,以维护研究的完整性和参与者的安全,然而,在国际环境中进行艾滋病研究可能会面临挑战:研究乌干达和俄罗斯符合抗逆转录病毒疗法(ART)试验入组标准的研究参与者中,检测不到 HIV 病毒载量的比例出乎意料地高:2012 年至 2015 年期间,从圣彼得堡的临床和非临床研究机构招募了具有艾滋病病毒感染记录和抗逆转录病毒疗法(ART)免疫状态的俄罗斯参与者。乌干达的参与者是 2011 年至 2014 年期间从姆巴拉拉地区转诊医院招募的,他们通过快速诊断检测证实感染了艾滋病病毒,并在诊所数据库中记录为抗逆转录病毒疗法无效者。对基线样本进行了艾滋病毒病毒载量检测;俄罗斯的检测下限为 500 拷贝/毫升,乌干达为 40 拷贝/毫升。由于检测不到病毒血症的参与者比例出乎意料地高,因此进行了额外的检测:酶联免疫吸附试验艾滋病毒检测和抗逆转录病毒疗法检测:在俄罗斯,16%(58/360)的人检测不到病毒血症;3%(9/360)的人再次检测出艾滋病毒阴性,4%(13/360)的人抗逆转录病毒疗法检测呈阳性。在乌干达,11%(55/482)的人检测不到病毒血症;5%(26/482)的人再次检测出艾滋病毒阴性,而结论是:在俄罗斯和乌干达,检测不到病毒血症的人在接受抗逆转录病毒疗法时检测结果呈阳性:在俄罗斯和乌干达,检测不到病毒血症的比例远高于预期的抗逆转录病毒疗法免疫组群。研究参与者分类错误的原因是快速诊断检测对 HIV 的误诊以及抗逆转录病毒疗法使用情况的不准确统计。HIV确诊检测可以提高符合HIV感染入组标准的参与者的准确性,同时也可以加强对抗逆转录病毒疗法免疫组群用药情况的检查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
HIV Clinical Trials
HIV Clinical Trials 医学-传染病学
CiteScore
1.76
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
期刊最新文献
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006). Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1